z-logo
Premium
Effect of cytochrome c modification with co‐polymer on its apoptotic activity for cancer treatment (LB248)
Author(s) -
Figueroa Miranda Cindy,
MoralesCruz Moraima,
Suarez Bethzaida,
Griebenow Kai
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb248
Subject(s) - hela , apoptosis , cytochrome c , viability assay , cytotoxicity , cancer cell , chemistry , endocytosis , mtt assay , biochemistry , in vitro , microbiology and biotechnology , cell , pharmacology , cancer , biology , genetics
Treating cancer, while avoiding devastating side effects, has been a challenge throughout the years. Active targeted delivery has been extensively studied to overcome the inherent adverse effects of anticancer therapy. The apoptotic protein cytochrome c (cyt c) is highly effective at causing cancer cells cytotoxicity but as most proteins, its delivery is challenging. In this project, we synthesized a co‐polymer of hyaluronic acid (HA) and folic acid (FA) followed by cyt c binding. Both compounds of the co‐polymer were selected due to their receptors overexpression on cancer cells surface allowing endocytosis of the cyt c system. We used TNBSA assay to determine the amount of modified lysines in cyt c when reacted to HA‐FA: 2.1 ± 0.4. The residual activity of the protein was measured before and after its incorporation in HA‐FA using a caspase cascade assay which showed caspase activation by cyt c‐HA‐FA: 105 ± 1 % while HA‐FA did not activate caspase: 1.6 ± 0.8 %. CD spectroscopy showed minor changes in heme group and tertiary structure of cyt c following modification. HeLa cells were incubated with cyt c‐HA‐FA (0.1 mg/ml) to measure cell viability with MTS assay. Cell viability was measured after 2 and 6 hours of incubation: 108 ± 14 % and 83 ± 8 %, respectively. According to these results we successfully synthesized a promising drug delivery system for anticancer applications. Grant Funding Source : Supported by NIH Research Initiative for Scientific Enhancement (RISE) Program with grant number: 2R25GM061151‐12.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom